SCHEDULE: Select Medical to Go Private in $16.50/Share Merger

Select Medical Holdings Corporation has agreed to be acquired by Stallion Intermediate Corporation for $16.50 per share in cash, with key management and an equity investor rolling over significant equity.

Summary

• Select Medical Holdings Corporation (the "Company") will merge with Stallion MergerSub Corporation, a wholly-owned subsidiary of Stallion Intermediate Corporation ("Parent"), with the Company surviving as a wholly-owned subsidiary of Parent.
• Unaffiliated shareholders will receive $16.50 in cash per share for their Eligible Shares.
• Certain existing shareholders, including Robert A. Ortenzio, Martin F. Jackson, and various trusts/estates (collectively, "Rollover Holders"), will contribute approximately 14.3 million shares to Parent in exchange for equity interests in Parent, rather than receiving cash.
• The Company's Special Committee and Board of Directors unanimously approved the merger, deeming it fair and in the best interests of the Company and its unaffiliated stockholders.
• The transaction is financed by an $880 million equity commitment from WCAS XIV, L.P. (the "Equity Investor") and a $1 billion debt financing commitment from JPMorgan Chase Bank, N.A., Wells Fargo Bank, National Association, and Wells Fargo Securities LLC.
• The merger is subject to customary closing conditions, including shareholder approvals (both overall and unaffiliated shareholder majority), regulatory clearances (HSR Act and healthcare), and the absence of a Company Material Adverse Effect.
• The merger agreement includes termination fees: $66,504,813 payable by the Company under certain circumstances (e.g., accepting a superior proposal) and $133,009,627 payable by Parent if it fails to close after conditions are met.
• The Rollover by certain shareholders is intended to qualify as a tax-free Section 351 contribution for United States federal and applicable state and local income tax purposes.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development for unaffiliated shareholders, offering a clear cash exit at a price deemed fair by an independent committee, while also ensuring continuity of management and strategic direction under private ownership.

Positives

• Unaffiliated shareholders receive a fixed cash price of $16.50 per share, providing liquidity and certainty of value.
• The Company's Special Committee, composed of independent directors, unanimously determined the merger to be fair and in the best interests of unaffiliated stockholders, supported by a fairness opinion from Goldman Sachs & Co. LLC.
• Key management (Robert A. Ortenzio, Martin F. Jackson) and a significant equity investor (WCAS XIV, L.P.) are rolling over a substantial portion of their equity, indicating continued alignment and belief in the long-term value of the company post-merger.
• The financing for the transaction is fully committed through equity and debt commitment letters, reducing funding uncertainty.
• Continuing employees will receive no less favorable base salary/wage and target cash incentive opportunities for one year post-closing, along with substantially comparable broad-based welfare benefits.

Negatives

• The transaction will result in the delisting of Company Shares from the NYSE and deregistration under the Exchange Act, removing public trading liquidity for existing shareholders who do not roll over their shares.
• Shareholders who do not roll over their shares will no longer participate in the future growth or potential upside of the Company.
• The Company is subject to restrictions on its interim operations, including limitations on significant capital expenditures, debt incurrence, and material contract changes, which could limit strategic flexibility prior to closing.
• The Company is obligated to pay a termination fee of $66,504,813 if the agreement is terminated under certain circumstances, such as accepting a superior proposal, which could deter other bidders.
• The transaction involves significant debt financing ($1,000,000,000), which will increase the consolidated total indebtedness of Parent and its subsidiaries post-closing.

Risks

• **Regulatory Approval Risk**: The merger requires HSR Act clearance and other governmental approvals, which may not be obtained or could be subject to conditions that materially delay or prevent consummation.
• **Shareholder Approval Risk**: The merger requires approval from a majority of outstanding shares and a majority of unaffiliated shares, which may not be obtained.
• **Financing Risk**: While financing is committed, there is always a risk that the debt financing may not be funded at closing, although Parent is obligated to use reasonable best efforts.
• **Company Material Adverse Effect**: The merger is conditioned on no "Company Material Adverse Effect" occurring between the agreement date (March 2, 2026) and the closing, which could allow Parent to terminate the agreement.
• **Litigation Risk**: Stockholder litigation related to the merger could be brought against the Company or its directors, potentially delaying or preventing the merger.
• **Integration Risk**: Post-merger, there are inherent risks associated with integrating the Company into Parent's structure and operations.
• **Tax Treatment Risk**: The intended tax-free treatment of the Rollover as a Section 351 contribution is subject to final determination.

Future Outlook

The Company anticipates becoming a wholly-owned subsidiary of Stallion Intermediate Corporation, leading to its delisting from the NYSE and deregistration under the Exchange Act. The Rollover Holders, including key management, will maintain an equity stake in the private entity, signaling their continued commitment to the Company's future under private ownership.

Management Comments

• The Special Committee has unanimously determined that it is fair to and in the best interests of the Company and the holders (other than any Parent Affiliated Stockholders) of shares of the Company's common stock... for the Company to enter into this Agreement and declared this Agreement and the transactions contemplated by this Agreement advisable.
• The Company Board, acting upon the Special Committee Recommendation, has determined that it is fair to and in the best interests of the Company and holders of Company Shares (including the Unaffiliated Company Stockholders) for the Company to enter into this Agreement and declared this Agreement and the transactions contemplated by this Agreement advisable.
• Robert A. Ortenzio co-founded the Issuer and his present principal occupation or employment is serving as Executive Chairman of the Board of Directors of the Issuer.
• Martin F. Jackson's present principal occupation or employment is serving as Senior Executive Vice President of Strategic Finance and Operations of the Issuer.

Industry Context

StockSavvy.ai notes that the healthcare sector continues to attract significant private equity interest, driven by stable demand and opportunities for operational efficiencies and strategic realignment away from public market pressures. This acquisition aligns with a broader trend of private equity firms seeking to acquire established healthcare providers, often with the aim of long-term value creation through strategic investments and potentially less short-term market scrutiny.

Comparison to Industry Standards

• The per-share merger consideration of $16.50 will be evaluated by investors against recent comparable transactions in the healthcare services sector, particularly those involving specialized medical facilities or rehabilitation services.
• The termination fees, $66.5 million for the Company and $133 million for Parent, will be compared to typical percentages of transaction value in similar-sized private equity-backed take-private deals to assess their deterrent effect and reasonableness.
• The rollover of equity by key management and founders is a common feature in private equity buyouts, aligning their interests with the new private owners, similar to transactions involving companies like Envision Healthcare or TeamHealth in the past.

Management Changes

Corporate Governance

Legal Proceedings

• The Company is not aware of any pending or threatened proceedings that would reasonably be expected to have a Company Material Adverse Effect.
• The Company is not subject to any outstanding order that materially restricts its business or would prevent the merger.
• The agreement includes provisions for handling "Transaction Litigation" (stockholder litigation related to the merger), requiring prompt notification to Parent and the right for Parent to participate in defense and settlement.

Related Party Transactions

• Robert A. Ortenzio (Executive Chairman), Martin F. Jackson (Senior Executive Vice President), and various trusts/estates associated with the Ortenzio family are "Rollover Holders."
• These Rollover Holders are entering into "Rollover Agreements" to contribute their Company Shares to Parent in exchange for equity in Parent, rather than receiving cash. This is a significant related-party transaction as it aligns their interests with the acquiring private equity firm.
• An "Interim Investors Agreement" was entered into by Parent, Merger Sub, WCAS Investor, Robert A. Ortenzio, and Martin F. Jackson, governing their relationship and actions regarding the merger.
• The WCAS Investor will receive an $11,000,000 "resource group services fee" if the transactions are consummated.

Stakeholder Impact

• **Shareholders (Unaffiliated)**: Will receive $16.50 per share in cash, providing a clear exit and liquidity. They will no longer hold shares in a publicly traded company.
• **Shareholders (Rollover Holders)**: Will exchange their Company Shares for equity in Parent, maintaining an ownership stake in the private entity and aligning their interests with the acquiring private equity firm. They will not receive cash for these shares.
• **Employees**: Continuing employees in the U.S. will receive no less favorable base salary/wage and target cash incentive opportunities for one year post-closing, along with substantially comparable broad-based welfare benefits. Service credit will be given for vesting and eligibility in Parent's benefit plans.
• **Customers/Suppliers/Creditors**: The Company is obligated to use reasonable best efforts to maintain existing relations and goodwill with these parties.
• **Management**: Key management (Robert A. Ortenzio, Martin F. Jackson) are rolling over equity and continuing in their roles, suggesting stability in leadership.

Next Steps

• Preparation and filing of a proxy statement and Schedule 13e-3 with the SEC.
• Company to conduct a broker search and set a record date for the Stockholders Meeting.
• Convene a Company Stockholders Meeting to obtain Requisite Company Stockholder Approvals.
• Obtain HSR Act clearance and other necessary governmental approvals.
• Negotiate, execute, and deliver definitive financing agreements.
• Consummate the Merger, leading to the Company becoming a wholly-owned subsidiary of Parent.
• Delisting of Company Shares from the NYSE and deregistration under the Exchange Act.

Key Dates

Recommendation

The acquisition of Select Medical Holdings Corporation at $16.50 per share in cash, following a unanimous recommendation from an independent Special Committee and Board, presents a compelling opportunity for unaffiliated shareholders to realize immediate value. The involvement of a major private equity firm (WCAS XIV, L.P.) and the rollover of significant equity by key management suggest a strong belief in the company's underlying value and future prospects under private ownership. For investors seeking a low-risk, short-term return, buying shares below the $16.50 offer price (if available) to capture the spread until closing is a viable strategy. The committed financing and robust governance process, including unaffiliated shareholder approval, mitigate execution risks.

Keywords

Merger Agreement, Acquisition, Healthcare, Private Equity, SEC Filing, Stockholder Approval, Regulatory Approval, Cash Consideration, Rollover Equity, Delisting, Deregistration, Stallion Intermediate Corporation, Select Medical Holdings Corporation, WCAS XIV L.P., Debt Financing, Equity Financing, Corporate Governance